DK3299030T3 - Parenterale norovirus-vaccineformuleringer - Google Patents

Parenterale norovirus-vaccineformuleringer Download PDF

Info

Publication number
DK3299030T3
DK3299030T3 DK17199372.8T DK17199372T DK3299030T3 DK 3299030 T3 DK3299030 T3 DK 3299030T3 DK 17199372 T DK17199372 T DK 17199372T DK 3299030 T3 DK3299030 T3 DK 3299030T3
Authority
DK
Denmark
Prior art keywords
vaccine formulations
norovirus vaccine
parenteral
parenteral norovirus
formulations
Prior art date
Application number
DK17199372.8T
Other languages
English (en)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3299030(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Application granted granted Critical
Publication of DK3299030T3 publication Critical patent/DK3299030T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK17199372.8T 2011-07-11 2012-07-11 Parenterale norovirus-vaccineformuleringer DK3299030T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11
EP12811916.1A EP2731621B1 (en) 2011-07-11 2012-07-11 Parenteral norovirus vaccine formulations

Publications (1)

Publication Number Publication Date
DK3299030T3 true DK3299030T3 (da) 2022-09-05

Family

ID=47506489

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17199372.8T DK3299030T3 (da) 2011-07-11 2012-07-11 Parenterale norovirus-vaccineformuleringer

Country Status (29)

Country Link
US (5) US9801934B2 (da)
EP (3) EP3299030B1 (da)
JP (2) JP6208659B2 (da)
KR (1) KR102096937B1 (da)
CN (3) CN103874507A (da)
AU (2) AU2012282658B2 (da)
BR (1) BR112014000656A2 (da)
CA (1) CA2841356C (da)
CL (1) CL2014000082A1 (da)
CR (2) CR20190540A (da)
DK (1) DK3299030T3 (da)
DO (2) DOP2014000004A (da)
EA (3) EA035442B1 (da)
EC (1) ECSP14013201A (da)
ES (2) ES2656527T3 (da)
GE (1) GEP201706668B (da)
HK (2) HK1199202A1 (da)
IL (1) IL230356B (da)
MA (1) MA35414B1 (da)
MX (2) MX379496B (da)
MY (1) MY170746A (da)
PE (1) PE20140845A1 (da)
PH (3) PH12021551773A1 (da)
PL (2) PL2731621T3 (da)
SG (1) SG10201605644WA (da)
TN (1) TN2014000008A1 (da)
UA (1) UA117732C2 (da)
WO (1) WO2013009849A1 (da)
ZA (2) ZA201401012B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
AU2014329403B2 (en) 2013-10-03 2020-10-08 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
US20160310412A1 (en) 2013-12-16 2016-10-27 Takeda Pharmaceutical Company Limited Microneedle
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
CA3061678A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11633467B2 (en) 2018-02-15 2023-04-25 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
WO2021140524A1 (en) 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
AU2022248473B2 (en) 2021-03-29 2026-03-05 Denka Company Limited Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
CA2133339A1 (en) 1992-04-08 1993-10-09 Jennifer S. Rota Wild-type measles virus glycoproteins: vaccine and detection method therefor
JPH08500250A (ja) 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
IL132201A0 (en) 1997-04-08 2001-03-19 Merck & Co Inc Stabilized human papillomavirus formulations
WO1998050071A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
PL347472A1 (en) 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
AU770809B2 (en) 1998-12-17 2004-03-04 Merck Sharp & Dohme Corp. Synthetic virus-like particles with heterologous epitopes
KR20010093290A (ko) * 1999-02-05 2001-10-27 폴락 돈나 엘. 사람 파필로마바이러스 백신 제제
EP1186890B1 (en) 1999-06-22 2013-01-02 Japan as Represented by Director-General of National Institute of Infectious Diseases Srsv detection kit
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US7041500B2 (en) 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2486118A1 (en) 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
DE602004020189D1 (de) 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
JP2006518748A (ja) 2003-02-20 2006-08-17 ベクトン・ディキンソン・アンド・カンパニー 改良されたワクチン接種のための大気圧噴霧凍結乾燥によって作製される組換えブドウ球菌エンテロトキシンｂ（＜ｓｂ＞ｒ＜／ｓｂ＞ｓｅｂ）の粉末処方物
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
US20050152911A1 (en) 2003-09-24 2005-07-14 Montana State University Norovirus monoclonal antibodies and peptides
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP1846028A4 (en) 2005-01-05 2010-06-30 Philadelphia Health & Educatio TRANSPORT, BIOACTIVE SUBSTANCES AND VIRAL VACCINES
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
PL1868642T3 (pl) 2005-03-18 2013-10-31 Cytos Biotechnology Ag Białka fuzyjne alergenów kocich i ich zastosowania
CN101287489A (zh) 2005-06-01 2008-10-15 陶氏环球技术公司 多价病毒样颗粒的生产
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
ES2577833T3 (es) * 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
HUE028605T2 (en) * 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
US8648229B2 (en) 2007-09-12 2014-02-11 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
SG10201601660YA (en) * 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR101793161B1 (ko) 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
WO2010084298A1 (en) * 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use
ES2552383T3 (es) * 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CA2787666A1 (en) * 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
CN102905728B (zh) * 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
GB2573406B (en) 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
CN112292390A (zh) 2018-05-03 2021-01-29 得克萨斯大学体系董事会 经工程改造以在免疫检查点阻断的情况下表达嵌合抗原受体的自然杀伤细胞
US20210308249A1 (en) 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
EP3924467A1 (en) 2019-02-15 2021-12-22 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy

Also Published As

Publication number Publication date
MX2014000411A (es) 2014-08-26
JP6613259B2 (ja) 2019-11-27
EP2731621B1 (en) 2017-11-01
PL3299030T3 (pl) 2022-12-05
SG10201605644WA (en) 2016-09-29
ZA201401012B (en) 2015-05-27
EA201792407A3 (ru) 2018-07-31
WO2013009849A1 (en) 2013-01-17
AU2012282658B2 (en) 2014-11-27
NZ620865A (en) 2015-08-28
EA201490258A1 (ru) 2014-05-30
PE20140845A1 (es) 2014-08-03
KR102096937B1 (ko) 2020-04-03
US10675341B2 (en) 2020-06-09
KR20140066160A (ko) 2014-05-30
EA202090699A2 (ru) 2020-07-31
EP4112074A1 (en) 2023-01-04
AU2012282658A1 (en) 2013-03-14
NZ710919A (en) 2017-12-22
PL2731621T3 (pl) 2018-10-31
MA35414B1 (fr) 2014-09-01
CN105031637A (zh) 2015-11-11
US20210085778A1 (en) 2021-03-25
US20130273102A1 (en) 2013-10-17
US9801934B2 (en) 2017-10-31
CA2841356A1 (en) 2013-01-17
JP6208659B2 (ja) 2017-10-04
CN108567975A (zh) 2018-09-25
AU2015200836A1 (en) 2015-03-12
JP2014520852A (ja) 2014-08-25
MX356586B (es) 2018-06-05
US20230338503A1 (en) 2023-10-26
TN2014000008A1 (en) 2015-07-01
EA029470B1 (ru) 2018-03-30
CL2014000082A1 (es) 2014-07-04
PH12018501515B1 (en) 2022-02-18
EP2731621A4 (en) 2015-03-25
EA035442B1 (ru) 2020-06-17
CN103874507A (zh) 2014-06-18
HK1198136A1 (en) 2015-03-13
DOP2014000004A (es) 2014-10-31
EP3299030A1 (en) 2018-03-28
BR112014000656A2 (pt) 2017-02-14
PH12018501515A1 (en) 2019-02-04
PH12021551773A1 (en) 2022-08-01
CR20140069A (es) 2014-06-27
MX379496B (es) 2025-03-11
HK1215154A1 (zh) 2016-08-19
DOP2022000030A (es) 2022-06-30
GEP201706668B (en) 2017-05-25
ECSP14013201A (es) 2014-05-31
CR20190540A (es) 2022-04-04
AU2015200836B2 (en) 2016-08-25
MY170746A (en) 2019-08-27
EP3299030B1 (en) 2022-06-08
EP2731621A1 (en) 2014-05-21
UA117732C2 (uk) 2018-09-25
CA2841356C (en) 2022-03-01
US20160000899A1 (en) 2016-01-07
US20180185468A1 (en) 2018-07-05
IL230356B (en) 2019-05-30
EA201792407A2 (ru) 2018-03-30
US9867876B2 (en) 2018-01-16
US11701420B2 (en) 2023-07-18
HK1199202A1 (en) 2015-06-26
JP2017214357A (ja) 2017-12-07
ES2656527T3 (es) 2018-02-27
EA202090699A3 (ru) 2020-11-30
ES2926487T3 (es) 2022-10-26
ZA201500915B (en) 2016-06-29
PH12014500093A1 (en) 2014-03-17

Similar Documents

Publication Publication Date Title
BR112014000656A2 (pt) formulações de vacina parenteral contra norovírus
PL2684880T3 (pl) Pochodna dispiropirolidyny
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP2748500A4 (en) BRACKET
EP2673344A4 (en) STABLE BIO OIL
DE102011100082A8 (de) Traygreifvorrichtung
EP2789316A4 (en) CARRIER
DK2673539T3 (da) Rør
BR112014000879A2 (pt) deflegmador
HUE044772T2 (hu) Immunogén készítmény
CO6960543A2 (es) 2-tiopirimidinonas
BR112014005756A2 (pt) vacina
EP2800129A4 (en) CONNECTION STRUCTURE
EP2690041A4 (en) LONG MEDIUM
FI20116167L (fi) Järjestely
IL231660A0 (en) Composition
PL2762466T3 (pl) Pochodna fenylu
FR2975564B1 (fr) Charrue
DE112011104936A5 (de) Stanzstauchniet
EP2763699A4 (en) VACCINE
HRP20181667T1 (hr) Pripravak
DK2672817T3 (da) Forbedrede insekticide formuleringer
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator